ANTIVIRAL EFFECTS OF FOSCARNET AND GANCICLOVIR THERAPY ON HUMAN-IMMUNODEFICIENCY-VIRUS P24 ANTIGEN IN PATIENTS WITH AIDS AND CYTOMEGALOVIRUS RETINITIS

Authors
QUINN TC JABS DA HOLBROOK JT HARDY WD POLSKY B LEWIS RA CLOGSTON P FAINSTEIN V GROSS R SAMO T TUTTLE C APUZZO L BARTLETT J DUNN JP ELDRED L FEINBERG J FLYNN T KING R BARRON B GREENSPAN D LECOUNT C PEYMAN G FRANKLIN R HEINEMANN M SQUIRES K WISECAMPBELL S FRIEDMAN AH CHEUNG TW JUSTIN N TEICH SA SACKS H SEVERIN C FRIEDBERG DN ADDESSI A DIETERICH D LAFLEUR F WEINBERG D JAMPOL L MURPHY R NAUGHTON K HENDERLY D HOLLAND GN CHAFEY S FALL H KIMBRELL C MACARTHUR LJ FREEMAN WR MEIXNERT L PETERSON TJ QUICENO JI RICKMAN L SIMANELLO MA SPECTOR S ODONNELL J HOFFMAN J IRVINE A JACOBSON M LARSON J SEIFF S WARNER L DAVIS J CHUANG E ESPINAL M MENDEZ P CHEESEMAN SH GITTINGER J HAUBRICH R KACHADOORIAN H TOLSON K BROWNBELLAMY J KLEMM AC MARKOWITZ JA MEINERT CL AMENDLIBERCCI A COLESON L COLLINS KL COLLISON BJ DODGE J DONITHAN M EWING C FINK N GERCZAK C ISAACSON MR KAPLANGILIPIN A HUFFMAN R LEVINE CR NOWAKOWSKI DJ SMITH M TONASCIA J VANNATTA ML AGRESSEGAL M ARMSTRONG J BROTHERS R HUBBARD L HURLBURT D MAGLI Y MINER K THOMAS S VANDERHOOFYOUNG M STEWART G HUGHES R LEEF J PALMER S MOWERY R ELLENBERG S KORVICK J DAVIS MD CLARK T MERIN L SATTLER F JORDAN C MILLS J BROWN BW CONWAY B GRIZZLE J NUSSENBLATT R PHAIR J SMITH H KLINE R MOSS M CARELLA A
Citation
Tc. Quinn et al., ANTIVIRAL EFFECTS OF FOSCARNET AND GANCICLOVIR THERAPY ON HUMAN-IMMUNODEFICIENCY-VIRUS P24 ANTIGEN IN PATIENTS WITH AIDS AND CYTOMEGALOVIRUS RETINITIS, The Journal of infectious diseases, 172(3), 1995, pp. 613-621
Citations number
53
Categorie Soggetti
Infectious Diseases
Journal title
The Journal of infectious diseases → ACNP
ISSN journal
00221899
Volume
172
Issue
3
Year of publication
1995
Pages
613 - 621
Database
ISI
SICI code
0022-1899(1995)172:3<613:AEOFAG>2.0.ZU;2-W
Abstract
To examine whether the prolonged survival seen in patients treated wit h foscarnet compared with those treated with ganciclovir was due to a direct effect on human immunodeficiency virus (HIV) replication, HIV p 24 antigen was measured. Of 71 receiving foscarnet, 54% were p24 antig en-positive at enrollment (vs. 44% of 79 receiving ganciclovir). By im mune complex-dissociated (ICD) p24 antigen analysis, 87% and 78%, resp ectively, were positive. After 1 month of treatment, there was a signi ficant decline in standard (mean decline, 10.1 pg/mL) and ICD (mean, 3 9.6 pg/mL) p24 antigen in both groups (P = .0001). Mortality was great er in those who were ICD p24 antigen-positive than in those -negative at baseline (P = .03) and in subjects with an increase in ICD p24 anti gen than in those with a decline (P = .09). Thus, each drug had a supp ressive effect on circulating p24 antigen, which was predictive of imp roved survival. The inhibitory effect on CMV replication may have a be neficial effect on limiting HIV replication.